America's Real China Trade Problem Is Hidden in Plain Sight
Trump is in Beijing negotiating planes and soybeans. The structural exclusion of America's most competitive industries remains entirely off the table.
President Donald Trump is in Beijing today for the first state visit by an American president to China in nearly nine years. The expected outcomes have been telegraphed for weeks: Boeing aircraft orders, agricultural purchase commitments, a tariff truce extension, and a new bilateral Board of Trade framed as the architecture for a more stable relationship. Both sides will present this as progress. On the narrow terms of the negotiation, it is.
The narrower the terms, the more you are conceding.
I spent a decade based in Shanghai, advising American companies on how to compete in the Chinese market. The companies that succeeded earned it. They localized their products, hired well, understood what Chinese customers actually wanted, and competed on Chinese terms. American companies have no inherent claim to Chinese market share. They have to deserve it.
But the argument here is different. It is about what sectors get to compete at all.
The United States runs a structural trade deficit with China because the two economies are exchanging things of fundamentally different value. China exports advanced manufactured goods: electronics, industrial machinery, semiconductors, and an expanding range of sophisticated products that move steadily up the value chain. The United States exports agricultural commodities and commercial aircraft. You cannot close that kind of gap by selling more of either. No volume of soybeans offsets a deficit built on advanced manufactured goods. No Boeing order of any realistic size dents the deficit because of the composition of what the two countries are actually trading with each other.
The path to genuine rebalancing runs through the sectors where American companies have real competitive advantage: technology platforms, cloud infrastructure, financial services, pharmaceutical innovation. These are, not coincidentally, precisely the sectors where China’s regulatory architecture is most deliberately constructed to exclude foreign competition. The tariff debate focuses on goods because goods are visible and countable. The exclusion of American software and services is harder to photograph. That does not make it less consequential.
China’s Great Firewall functions as market protection at continental scale. It covers more than 200,000 domains, blocks every major American internet platform, and ensures that Baidu, Alibaba, and Tencent face no meaningful foreign competition in the world’s largest internet market. Freedom House’s 2025 internet freedom report scored China at 9 out of 100, dead last globally alongside Myanmar for the fifteenth consecutive year. Researchers have documented a parallel system that restricts foreign access to Chinese government websites, extending the logic of exclusion in both directions. The wall has not loosened. It has grown more sophisticated.
The barriers in cloud computing and data services are equally deliberate. China’s Network Data Security Management Regulations, effective January 1, 2025, require that personal data and important data generated in China remain on Chinese servers. Cross-border data transfers require government security assessments and certifications. A cybersecurity law amendment effective January 1, 2026 imposes penalties of up to 5 percent of prior-year global turnover for violations. Any foreign technology company operating at scale in China must build entirely separate China-only infrastructure and make its systems available for inspection under Chinese legal process. America’s most valuable technology businesses are structurally limited to operating in China as guests of the Chinese regulatory state, on terms that make genuine competition impossible.
In pharmaceuticals, the discrimination is precisely calibrated. China’s National Reimbursement Drug List, which governs coverage across the public hospital network that represents roughly 70 percent of the country’s drug market, released its 2025 update effective January 1, 2026. The pattern was consistent with every prior year: foreign drugs without domestic competition were added; foreign drugs in therapeutic categories where Chinese manufacturers have established alternatives were systematically excluded. No imported PD-1 inhibitor, the class of cancer immunotherapies where American companies hold significant scientific leads, has ever appeared on the list. China’s health authority frames the exclusion as a price dispute. The mechanism functions as exclusion in any therapeutic category where the domestic pharmaceutical industry has matured enough to compete.
The tariff war of the past year is the most expensive demonstration of this problem on record. Tariffs on Chinese goods peaked at 145 percent in April 2025. The bilateral goods deficit narrowed to $202.1 billion in 2025, down from $295.5 billion the prior year, the lowest figure since 2006. This was widely treated as a win. It was not. US imports from China fell 29.7 percent, which accounts for most of the narrowing. US exports to China fell 25.8 percent at the same time, as China curtailed purchases of American agricultural products in retaliation. Both sides traded less with each other, which is a different thing from rebalancing. In the same year, the overall US goods trade deficit with the world hit a record $1.24 trillion. Trade that previously moved through China migrated to Vietnam, Taiwan, and India. The structural conditions that generated the imbalance were untouched throughout the entire cycle. The deficit shrank by mutual suppression. It did not shrink by opening.
This week’s summit is negotiating on the same terrain. The Board of Trade, which USTR Greer has described as focused on “non-sensitive tradeable goods” and reducing mutual dependency, was characterized by The Wire China’s pre-summit analysis as a signal that “the US has given up trying to change China’s economy through outside pressure.” Greer made the underlying logic explicit at a conference in April: “We’re not going to do what Washington tried to do for 25 years, which is go to the Chinese and say, ‘We’re going to pretend they’re going to become a market economy.’” Treasury Secretary Bessent, in his sharpest recent statement on structural barriers, flagged ahead of the summit that China’s regulatory posture “has a chilling effect on global supply chains.” The Great Firewall, the National Reimbursement Drug List, and the data localization regime are not on the agenda this week.
This dynamic produces a distorted narrative. When the United States imposes tariffs, it appears aggressive. China, which maintains one of the most sophisticated market exclusion systems in the world, presents itself as a defender of open trade. That framing completely obscures the degree to which Beijing has systematically protected its most strategically important industries from foreign competition while expecting full access to American markets in return. The Board of Trade formalization accepts that framing. It manages trade in goods without addressing the regulatory architecture that decides which American sectors are permitted to compete in China at all.
Genuine progress requires enforceable provisions on digital services access, transparent government procurement, and intellectual property protection, pursued alongside European and Asian allies who face the same structural discrimination. That is a harder negotiation than Boeing orders and soybean commitments. It is also the only negotiation that addresses the actual composition of the imbalance rather than its headline number. Until the barriers come down in technology, financial services, and pharmaceutical innovation, the trade deficit is being managed at the margin while the underlying problem is left entirely intact.
Adil Husain is a competitive strategist who advises CEOs on how to compete and grow in contested markets. He is the Founder and Editor-in-Chief of business media company The Intelligence Council, and Managing Director of the global advisory firm Emerging Strategy. He has spent 25 years advising C-level executives at global companies on competitive strategy, market entry, and international growth, with on-the-ground experience across China, Southeast Asia, and major emerging markets.
You can reach him here for a conversation: ahusain@emerging-strategy.com